Table 3.

Results

Outcome	Value
Patients de-labeled of their beta-lactam allergy, n (%)  Allergy interview alone  Oral amoxicillin challenge alone  Penicillin skin testing followed by oral amoxicillin challenge	25 (40) 15 (60) 8 (32) 2 (8)
Risk stratification, n (%)  No risk  Low risk  Moderate risk  High risk	16 (26) 24 (39) 21 (34) 1 (2)
Failure of oral amoxicillin challenge and/or penicillin skin testing, n (%)	0 (0)
Patient and/or caregiver refusal of intervention, n (%)	5 (8)
Reasons for ineligibility beyond beta-lactam interview, n (%)  Concomitant antihistamine or systemic steroid use  Current IgE or IgE-like reactions  Cephalosporin allergy  NPO status  Classified as high-risk	15 (60) 4 (16) 3 (12) 2 (8) 1 (4)
De-labeling prompting change in current antibiotic therapy, n (%)	5 of 25 (20)
Barriers to the de-labeling process, n (%)  Concomitant antihistamine or systemic steroid use  Patient, caregiver, or provider refusal of intervention  Insufficient resources or personnel for penicillin skin testing	15 (24) 8 (13) 4 (7)

IgE, immunoglobulin E